Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

1 article matching "C3 glomerulonephritis"

Clinical trialCLINICALTRIALSMar 26

New Clinical Trial: New Analytic Tools for aHUS and C3G Diagnosis (NCT05985122)

Researchers across 7 European countries are working together to develop better ways to diagnose two rare kidney diseases: atypical hemolytic-uremic syndrome (aHUS) and C3 glomerulonephritis (C3G). This study is enrolling 180 people, including patients with these conditions and healthy volunteers, to test new diagnostic tools that could help doctors identify these diseases more quickly and accurately.

WHY IT MATTERSThis trial is developing improved diagnostic tests for aHUS and C3G, which could help patients get diagnosed faster and start treatment sooner—critical since these complement-mediated kidney diseases can cause permanent kidney damage if left untreated.
Good to knowAtypical Hemolytic-Uremic Syndrome (aHUS)C3 Glomerulonephritis (C3G)Membranoproliferative GlomerulonephritisRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases